EVRY, France--(BUSINESS WIRE)--IntegraGen (FR0010908723 - ALINT), a leading player in genome analysis and the development and commercialization of molecular diagnostic tests for autism and oncology, announced today the signing of a distribution agreement with Genoma SA allowing the company to commercialize the autism spectrum disorder genetic risk assessment test IntegraGen has developed.
"Thanks to this agreement between Genoma and IntegraGen, physicians outside the U.S. will now be able to offer parents a genetic predisposition test for autism for their children who have developmental delays,” stated Dr. Bernard Courtieu, IntegraGen’s CEO. “This test will enable the earlier referral and diagnosis of children with autism spectrum disorder and aid clinicians to implement appropriate treatments when they are most effective, before the age of three years. We are particularly pleased that Genoma will market the test in Europe and in other markets outside of the United States. With many children in France and around the world being diagnosed with autism at an age which is too late to implement early interventional treatment options shown to improve outcomes, the utilization of this test will contribute to an earlier clinical diagnosis and improve the care of children with autism spectrum disorder.”
Genoma plans to eventually offer the test in all countries where it operates and will market the test for children with suspected developmental disorder or for children who have an older sibling previously diagnosed with autism spectrum disorder. Genoma will also provide parents consulting services in genetics and all diagnostic services for children and their parents.
Financial terms of the deal were not disclosed
IntegraGen is a company specialized in deciphering the human genome by performing genomic analyses for academic and private laboratories and developing diagnostic tools within the fields of oncology and autism. IntegraGen’s oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients. For autism, IntegraGen has developed the ARISk® Test, the first test marketed in the United States to assess the risk of autism spectrum disorder in children.
As of December 31 2014, IntegraGen had 34 employees and had generated revenue of €6 million in 2014. Based in the Evry Genopole, IntegraGen also has an office in the Cambridge, Massachusetts in the United States. IntegraGen is listed on Alternext of Euronext Paris (ISIN: FR0010908723 - Ticker: ALINT - PEA-SME).
For more information on IntegraGen visit www.integragen.com.